

Paul Long

Managing Director



ASX: LGP

Broker Meets Biotech Lunch

Thursday March 20th

Disclaimer

Disclaimer

This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its activities current as at the date of this presentation. The information in this presentation is of general background and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) (“Corporations Act”).

It should be read in conjunction with LGP’s other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire LGP’s shares or other securities. This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP.

No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee, representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.


Forward looking statements


Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP’s actual results, performance or achievements to differ from those referred to in this document. Accordingly, LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Past performance is no guarantee of future performance.


This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to LGP’s business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words ‘likely’, ‘estimate’, ‘project’, ‘intend’, ‘forecast’, ‘anticipate’, ‘believe’, ‘expect’, ‘may’, ‘aim’, ‘should’, ‘potential’ and similar expressions, as they relate to LGP and its management, are intended to identify forward-looking statements. Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of LGP to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

Acceptance

By accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.







What's next for this industry?



Will it fade into oblivion?

Or are we someway through the
shakeout and heading to the
domination phase



Is it really a market worth investing in?



Australia



Germany



UK



France, Poland



North America?




So, lets revisit the TAMS


Global Footprint

- LGP has supply arrangements for medicinal cannabis products into 11 countries
- LGP has grown its supply footprint since 2019, beginning in Australia and progressing through Europe including Germany, the UK, France, Italy and Poland

Market	Pop.	TAM 2024 ¹	TAM 2029 ¹
Europe	515m	\$2.50 billion	\$3.10 billion

KEY

-  Production facility and supplied market
-  Supplied market
-  Supply arrangements



1. <https://www.statista.com/outlook/hmo/cannabis/medical-cannabis>

Who wins in a Domination Phase?



Brand power



Economies of Scale



Early mover (not necessarily the first)



Shake out strategy – smart M&A



Regulatory experts



LGP most trusted Brand in AU and EU
#3 brand sold in AU
Highly successful brand segmentation



Already scaled for success and poised to exploit scale
(market, cost to produce....biggest site in EU)



- First in Australia
 - Top 5 in Germany/UK
 - One of only 3 in Italy
 - One of 2 in Denmark and France
 - One of ~10 in Poland
-

M&A runs on the board

Regulatory know-how and our trusted brand is our moat

You can't deny this market now... it's proven

Do your best to try and predict the move from shake out phase to domination phase?

Or back the big picture and look at the LGP fundamentals today:

1. 75m plus of net assets (mostly property)
2. CAGR of ~40% for 3-4 years
3. Annualised rev today of \$40m+
4. Cash flow positive
5. EU growth significant and upside TAM huge
6. Market cap of \$39m

